Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MULTIDET

Financiado

Cerrado

Multiplex qPCR detection and chemical analysis towards multifunctional diagnosis

Kidney Disease in England costs more than breast, lung, colon and skin cancer combined. In particular, chronic kidney disease (CDK) affects 10% of the population worldwide. This is bound to increase as our population ages and, if... ver más

14/09/2018

ELVESYS

88K€

Presupuesto del proyecto: 88K€

Líder del proyecto

ELVESYS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-09-14

INNOSUP-02-2016: European SME innovation Associate -... Specific Challenge:The lack of access to skills, to latest knowledge and capacity to manage innovati...

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ELVESYS

87.50K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 18 meses Fecha Inicio: 2017-03-02
Fecha Fin: 2018-09-14

Líder del proyecto

ELVESYS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 88K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Kidney Disease in England costs more than breast, lung, colon and skin cancer combined. In particular, chronic kidney disease (CDK) affects 10% of the population worldwide. This is bound to increase as our population ages and, if CKD is not detected early enough, the patient may progress to kidney failure which requires therapies (dialysis or transplantation) that are extremely costly and weighs heavily on healthcare budgets. Even though several cheap traditional tests already exist based on a diagnosis of urinal or blood samples, there is no technology available to measure both key RNA biomarkers of kidney diseases and perform traditional chemical analysis. The development of fast multiplex quantitative PCR (qPCR) technologies offers a unique opportunity to propose a Point of Care Test (PoCT) able to perform new multifunctional cheap diagnostics. By hiring an Innovation Associate with an expertise in microbiology and chemistry, ELVESYS wants to develop the first multifunctional, fast and affordable PoCT device for kidney disease diagnostics. This system will enable any practitioner to propose a diagnosis based on the simultaneous analysis of urinal and blood samples in a single test during the time of a visit to the doctor’s office. The Innovation Associate will benefit from ELVESYS expertise in the world fastest multiplex qPCR system to develop this first prototype. The MULTIDET project is relevant to bring a PoCT system to the market within the next couple of years. This system will bring ELVESYS to a pioneering position for multifunctional PoCT systems to solve medical and social issues of kidney diseases that weigh severely on the EU healthcare systems. This project will also allow ELVESYS to train an Innovation Associate in entrepreneurship so that they can later become part of the team or start their own spin-off company to commercialize the PoCT system developed.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores